1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.
September 2024 in “Cureus” This document discusses a case of pustulotic arthro-osteitis (PAO) and palmoplantar pustulosis (PPP) treated with adalimumab, an anti-TNF-α agent, which resulted in paradoxical skin reactions (PSRs) such as psoriasis-like rashes and acute hair loss. The treatment was switched to guselkumab, an anti-IL-23 p19 monoclonal antibody, which effectively managed both PAO/PPP and the PSRs. The document highlights that no PSRs have been reported with anti-IL-23 agents in PAO, and a study from Japan shows similar efficacy between guselkumab and adalimumab for PAO. It recommends using anti-IL-23 agents over adalimumab for PPP/PAO patients to avoid PSRs, especially since they are approved for refractory PPP in Japan.
September 2023 in “Journal of the American Academy of Dermatology” September 2023 in “Journal of the American Academy of Dermatology” 
January 2020 in “Journal of The European Academy of Dermatology and Venereology” In 2019, dermatology and venereology improved skin cancer imaging, advanced in treating skin conditions like psoriasis, and explored the skin microbiome's role in diseases.